|
Middle East Fertility Society Journal
Middle East Fertility Society
ISSN: 1110-5690
Vol. 9, Num. 1, 2004, pp. 25-30
|
Middle East Fertility Society Journal, Vol. 9, No. 1, 2004, pp. 25-30
DEBATE
Recurrent
miscarriage: Does any treatment help?
Comment by: El Sayed El Badawy Awad, M.D.Alexandria, Egypt
Code Number: mf04004
Recurrent pregnancy loss
is emotionally frustrating for couples experiencing loss and often is a
frustrating challenge for their medical teams. This dual frustration usually
results in recommendation of unsubstantiated test that are not necessarily
useful or adopting therapies of dubious efficacy.
This perhaps reflects
dilemmas and controversies which surround this subject starting from definition
up to advanced research, passing through etiology, investigations and treatment
modalities. The diversity and complexity of known etiologies and the wide
spectrum of unknown etiologies add to the frustration of both couples and
physicians. After every single case of miscarriage, the physician is usually
asked, "what was wrong?? a simple a logic question for which- in many
instances- the answer may be impossible.
Most
textbooks define recurrent pregnancy loss (RPL) as three or more consecutive
spontaneous abortions. This definition can be further subdivided into primary
(all pregnancies lost) or secondary (after a successful pregnancy). In many
clinical situations, the definition is altered to two or more consecutive
spontaneous abortions. If by chance alone, RPL should occur in 0.3-0.4% of
women. However, RPL affects almost 1% of women suggesting a specific underlying
cause in more than half such cases. Usually little clinical importance is
gained from extensive investigations of otherwise healthy couples who suffered
from only two spontaneous abortion, and their likelihood of having a subsequent
successful pregnancy is not less than 80%. On the other hand, the likelihood of
extensive and expensive investigations finding any relevant cause is less than
10%. It appears that a clear and consistent definition of three consecutive
losses is necessary to allow sensible questions to be asked and arrange
cost-effective investigations. This is also important to provide prognosis,
suggest possible remedies and guide further research.
The situation regarding
etiological factors is not far being complex. The incidence of chromosome
abnormality in spontaneously aborted conceptuses is more than 50% in first
trimester and 20% in 2nd trimester. Parental chromosomal rearrangements could
be found in 10% of couples of RPL in the form of translocations, inversions and
mosaicism. The woman is twice as likely as the man to be the carrier of these
chromosomal rearrangements. On the other hand, autosomal trisomies are the most
common defects found in 1st trimester miscarriages in addition to molecular
mutations.
Anatomical
etiological disorders include congenital uterine fusion abnormalities, cervical
incompetence or acquired uterine factors like fibroids, polyps or synechiae.
The controversy relating diagnosis and management of cervical incompetence is
well discussed in obstetric textbooks.
Other
important etiological factors include endocrinal, immunological, infectious,
environmental factors as well as thrombophilic defects.
An evident link is well
established between immunologic factors and adverse pregnancy outcome including
RPL but the main controversies lie in the validity and usefulness of different
investigations and modes of therapy. A long list of investigational tests
should not be applied in view of their limited experimental nature. Moreover,
the efficacy of therapies of disorders of materno-fetal alloimmune
relationships is doubtful at most or of limited value at best. These therapies
include allogenic leukocyte immunization and intravenous immunoglobulin
administration and other less tested therapies.
Different microbial
agents may be related to pregnancy loss, these include bacteria, viruses,
parasites and spirochetes. The theory that microbial infections can cause
pregnancy loss is present in literature since the turn of the 20th century with
discovery of brucellosis. Despite that, few studies to confirm that exist and
their results are inconsistent. In fact, infection is viewed as a rare of RPL,
hence the validity of famous infections screen is of little significance.
Equally important the use of empiric antibiotic therapy should be abandoned.
The impact of
environmental toxins and pollutants on pregnancy is unmistakable. This accounts
for more than 10% of adverse pregnancy outcome including RPL, malformations and
preterm birth. Occupational hazards like exposure to lead, mercury, ethylene
oxide, ionizing radiation, anesthetic gases are examples of environmental
factors. Social habits like smoking and alcohol consumption are additional
hazards for RPL. Moreover domestic factors like exposure to electromagnetic
fields, use of cellular phones, and video terminals should not be overlooked.
Identification of a single and definitive environmental factor as a cause of
RPL may be difficult in designing research but several caveats are to be
considered, such as gestational age at the time of exposure, amount, duration,
and frequency of exposure, genetic differences and susceptibility and
establishing a clear plausible cause-effect relationship.
Many cases of RPL are
characterized by defective placentation and the presence of microthrombi in the
placental vascular tree. This tendency for clotting or procoagulant state prior
to conception which is aggravated by pregnancy is well recognized as a cause of
adverse pregnancy outcome.
Since
reproductive failure is a continuum depending on the severity of the cause,
this thrombophilic defect may impair fertility, cause RPL, IUFD, growth
retardation, PIH or fetal distress at labor. The association between RPL and
acquired thrombophilic defects like antiphospholipid antibody syndrome (APLA)
is now firmly established. In recent years, the role of inherited thrombophilia
and RPL is under investigation. This deficiency of natural anticoagulants
include activated protein C resistance, antithrombin III deficiency, protein C
& protein S' deficiency.
Despite complexity of
pathways for clot formation, the therapy is now well defined in the form of low
dose aspirin and subcutaneous heparin with successful outcomes.
The complexity of the
situation made famous scientific bodies like ALOG and RCOG propose guidelines
for workup and management of cases of RPL. It is noteworthy to mention that
each local committee can propose local guidelines based on special relevant
local etiological factors and service provision available. But to sum up these
workups should be of maximum clinical usefulness to avoid unnecessary,
expensive and experimental investigations. Moreover, definitive therapies for definitive
causes should be preferred to empiric therapies.
REFERENCES
- Joseph
A Hill MD. Recurrent pregnancy loss in Maternal Fetal Medicine 4th ed. R.K.
Creasy, Resnik R. Published by W.B. Saunders 1999
- Stirrate
GM, Wardle PG. Recurrent miscarriage in High Risk Pregnancy- management
options. ed, by James DK, Steer PJ, Weiner CP, Gonik B. Publisher- W.B.
Saunders 1999
- American
College of Obstetrician and Gynecologists.
Committee on Practice Bulletins. Guidelines for Obstetricians-Gynecologists No
24, DC: ACOG. February 2001
- Royal
College of Obstetrician and Gynecologists.
Scientific Advisory Committee. London UK: RCOG June 2001
Prof. Dr. El Sayed El Badawy Awad
Professor of Obstetrics and Gynecology,
Faculty of Medicine, University
of Alexandria,
Alexandria, Egypt
Comment by: Aboubakr Elnashar, M.D.
Benha, Egypt
Recurrent miscarriage
(RM) is defined as the loss of three or more consecutive pregnancies before
viability. Some clinician favor changing the definition to two or more
consecutive losses (1), but the efficacy of commencing investigations after two
losses has not been established.
Causes of RM are
different from those of single sporadic miscarriage. Causes of RM should be
persistent & proved each time. Treatment of RM depends widely on whether a
definite cause has been found or whether it is finally classified as idiopathic
or unexplained. A definite cause can be established in only 50% (2) of cases
& several alleged causes are controversial & doubtful. In management of
RM many investigations are requested but few specific treatments are available.
So it is crucial for management of RM to define the cause & then to treat
depending on level-one evidence therapies.
Doubtful causes (poor
correlation between the cause & RM) of RM include uterine anatomic
abnormalities (retroversion or backward tilting of the uterus, mild
intrauterine adhesions, subserous fibroid, intramural fibroid less than 7 cm,
arcuate uterus), infections (toxoplasmosis, mycoplasma, chlamydia trachomatis,
L. monocytogenes, HSV, CMV), endocrine abnormalities (endometriosis, luteal
phase defect) & occupational exposure (herbicide spraying, electromagnetic
fields, chemical inhalation, anesthetic gases). So, the following
investigations are of no value in normal females with RM: cultures for bacteria
or virus; GTT or thyroid function tests, other antiphospholipid antibodies
other than anticardiolipn & lupus anticoagulant antibodies, antinuclear
antibodies, antithyroid antibodies, tests for thrombophilia, human leukocytes
antigen, maternal antipaternal antibodies (2). The following treatments are of
no value: leukocyte immunization, intravenous immunoglobulin & luteal phase
support with progesterone.
Possible
causes (good correlation between the cause & RM) of RM include genetic abnormalities,
uterine cavity abnormalities (congenital uterine malformation, submucous
fibroid, cervical incompetence, severe intrauterine adhesions), endocrine
abnormalities (uncontrolled diabetes mellitus, uncontrolled thyroid
dysfunction, PCOS), antiphospholipid syndrome, cigarette smoking & alcohol
consumption. So, the following investigations are required: peripheral blood
karyotyping of the parents, karyotyping of the abortus, pelvic ultrasonography
or hysteroscopy, anticardiolipn & lupus anticoagulant antibodies (2).
Treatment of antiphospholipid syndrome is low dose aspirin & low dose
heparin (3). Women with uterine septum should undergo hysteroscopic evaluation
& resection (2). Cervical cerclage should not be offered to women at low or
medium risk of mid trimester loss, regardless of cervical length by ultrasound
(4). The role of cervical cerclage for women who have short cervix on
ultrasound remains uncertain, as the number of randomized women are too few to
draw firm conclusions. No known therapy for decreasing the risk of RM in women
with PCOS (2). Suppression of LH secretion with GnRH agonist prior to
stimulation induction yielded no difference in outcome (5). Metformin has been
continued during pregnancy to prevent RM in polycystic ovary syndrome (6).
Unexplained RM is
diagnosed if the basic investigations (karyotyping, HSG or hysteroscopy,
anticardiolipn & lupus anticoagulant antibodies) are normal (2). Causes of
unexplained RPL include thrombophilia, hyperhomocystenemia, poor ovarian
reserve, thyroid autoantibodies, selenium deficiency and vitamin B12
deficiency. Heparin therapy may prevent RM in thrombophilia (7). No treatment
options have been proved beneficial in cases thyroid autoantibodies (8).
In absence of any cause,
it is difficult to propose a particular treatment regimen. Empirical therapy is
unnecessary (2). Reassurance, attendance at a dedicated early pregnancy
assessment clinic & informative & sympathetic counseling are associated
with successful pregnancy in 35-85% of cases. Often, the patient, who is not
prepared to accept that the chance of having successful pregnancy next time is
higher without pharmacological intervention, does not share this opinion.
Immunotherapy is not beneficial (9) & there is insufficient evidence to support
use of HCG in unexplained RM (10). Empirical treatment is usually prescribed
with aspirin, 75 mg/day, folic acid 0.5 mg/day & heparin in case of an
obstetric history of fetal death (7). Low dose aspirin did not improve
pregnancy outcome in unexplained RM (11).
REFERENCES
-
Regan
L. Recurrent miscarriage. BMJ 1991;302:543-4.
- ACOG
practice bulletin. Management of recurrent early pregnancy loss. Inter J Obstet
Gynecol 2002;78:179-90.
- Rai
R, Cohen H, Dave M, Regan L. Randomized controlled trial of aspirin &
aspirin plus heparin in pregnant women with recurrent miscarriage associated
with phospholipid antibodies. BMJ 1997;314:253-7.
- Drakely
A, Reborts D, Alfirevic Z. Cervical stitch (cerclage) for preventing pregnancy
loss in women. Cochrane Database Syst Rev 2003;(1):CD003253.
- Clifford
K, Rai R, Watson H, Franks S, Regan L. Does suppressing LH secretion reduce the
miscarriage rate? Results of randomized controlled trial. BMJ 1996;312:1508-11.
- Gluek C, Philips H, Cameron D, et al. Continuing
metformin throughout pregnancy in women with polycystic ovary syndrome appears
to safely reduce first trimester spontaneous abortion. Fertil Steril
2001;75:46-52.
- Milliez
M. Management of recurrent miscarriage. Egypt J Fertil Steril 2003;7:33-6
- Stagnaro-Green
A, Roman S, Colin R et al. Detection of at-risk pregnancy by means of highly
sensitive assays for thyroid autoantibodies. JAMA 1990;264:1422-5.
- Scott
JR. Immunotherapy for recurrent miscarriage (Cochrane Review). In: The Cochrane
library, issue 1,2002.Oxford: Update Software.
- Scott
JR, Pattison N. Human chorionic gonadotrophin for recurrent miscarriage.
(Cochrane Review). In: The Cochrane library, issue 1,2002.Oxford: Update
Software.
-
Rai
R, Backos M, Baxter N, et al. Recurrent miscarriage-An aspirin a day? Hum
Reprod 2000;15:2220-3.
Aboubakr Mohammed Elnashar, M.D.
Prof. of Obstetrics & Gynecology,
Benha University Hospital, Egypt,
E-mail: elnashar53@hotmail.com
Comment by:
Khaled R. Gaber, Ph.D.
Cairo,
Egypt
Miscarriage occurs in 10-15 % of pregnant
women (1),with a percentage of them at risk to lose their next
pregnancy. This risk rises to near 20 % after one miscarriage and approaches 40
% after 3 consecutive losses (2).The repetition of this tragedy,
recurrent pregnancy loss (RPL), magnifies the problem and may have serious
far-reaching consequences on the patient and her family. Hence, it necessitates
the establishment of an effective treatment protocol.
In
daily medical practice, rigidity is not recommended. It may be wise to start
the evaluation panel after the second loss, or even once it occurs. The start
of evaluation and the order of request for the tests greatly depend upon the
objective data in the couple and their familys medical history. Waiting for
another loss may not clarify the etiology, and may even aggravate the
psychological condition of the couple.
RPL is
a heterogeneous syndrome. Several factors are involved in the etiology, with
different modalities of treatment. These factors may be related to the
conception itself and are mostly genetic/chromosomal (preventive treatment).
Or, factors involved in the process of implantation and development of the
fetus: anatomic (surgical treatment), hormonal and immunologic factors (medical
therapy). The later group of factors is usually associated with maternal
medical complications. It should be noted that more than one factor might have
a role in the occurrence of pregnancy loss (PL) (3).The risk of
miscarriage is also increased by multiple pregnancy, poorly controlled
diabetes, infection, exposure to toxins and smoking.
Preventive treatment
Chromosomal
abnormalitiestend to cause abortion early in pregnancy. Over 50 %
of abortuses in the first trimester are chromosomally abnormal, whereas after
20 weeks only 10 % are abnormal (4, 5).If fetal tissues reveal abnormal
karyotype, parental studies are requested. Preventive treatment may be offered
if a partner shows chromosomal rearrangement. This may include: preimplantation
genetic diagnosis and transfer of only chromosomally normal embryos or through
prenatal diagnosis (amniocentesis, chorionic villous sampling) and counseling
for the risk of a live birth with serious birth defect.
Surgical treatment
The
prevalence of uterine malformationsin RPL is between 1.8 and 37.6 %
(6). Recently, three dimensional ultrasound and magnetic resonance imaging
appear promising in evaluating the anatomic factor. These techniques when
coupled with hysteroscopic surgery can have a role to overcome the
complications associated with open uterine surgery (post-operative infertility,
uterine scar rupture) in such abnormalities (6,7). I believe that
starting evaluation following the first miscarriage can greatly benefit this
group of patients, both in counseling and early treatment.
Traumatic
lesions are usually reported as the main cause of cervical incompetence.
Although cerclage operation is best performed by the end of the first
trimester, emergency cerclage with indomethacin, antibiotics and bed rest
appear a successful therapy if the condition is detected even by the end of the
second trimester with bulging membranes (8).
Medical therapy
The
debate concerning the role of follicular phase hormonal defecttreatment
and its role in RPL is mostly due to lack of controlled studies. The common
regimen of treatment in luteal phase defect (LPD) is medical, and includes:
Progesterone supplementation or induction with clomiphene citrate and
supportive doses of human chorionic gonadotrophin during the luteal phase. A
meta-analysis reported the existence of LPD as a clinically significant entity
first trimester miscarriage, and can be successfully treated with progesterone
administration (9).Several investigators reported failure of exogenous
progesterone administration after conception to show any benefit (10).However,
we have detected that nearly 20 % of the RPL in our clinic have LPD (based on
endometrial biopsy &/or hormonal evaluation), and that they benefited from
progesterone supplementation. Progesterone supplied during the luteal phase of
the cycle preceding conception gave better results than when started following
a positive pregnancy test.
Women with polycystic ovaries (PCO) are
at increased risk of RPL compared with regularly cycling women in the general
population. Studies revealed that pituitary desensitization with gonadotrophin
releasing hormone analogues has no effect on pregnancy outcome in women with
PCO c. Recently, it was reported that metformin administration during
pregnancy reduces first trimester PL in women with PCO.
RPL
related to immune dysfunction is increasingly recognized and is mostly related
to blood clotting disorders. Women with RPL associated with prior maternal or
fetal complications (preeclampsia, abruption, growth retardation) should be
screened for congenital thrombocytopenia and antiphospholipid antibodies
(APLAs). The chance of having successful pregnancy decreases with each PL. With
proper treatment the live birth rate reach 80 % (13). Treatment
protocol for RPL associated with immune dysfunction is completely empirical.
The most commonly used medications include different combination of:
antiplatelets, anticoagulants, and immunosuppressant therapy. Although the
safety of low-dose aspirin (LDA) during the first trimester of pregnancy is
still a matter of debate, it appears to be safe, with no reported major
complications (maternal or fetal) at this dose (60 - 150 mg/day). Treatment
with LDA is usually advised before conception and in combination with heparin
when pregnancy test is positive. The safety of heparin makes it the
thromboprophylaxis of choice. The low molecular weight heparin (LMWH) is now
more accepted and safe than the unfractionated heparin (UFH). This is due to
the lower risk of associated bone loss, bleeding and induced thrombocytopenia.
Also, its once-day subcutaneous injection makes it more accepted by the patient
(14).
Most
reports now agree that the combination of heparin and LDA is the standard
treatment and is superior to LDA alone (15, 16).The live birth rate
rises from 40 % in the single treatment to over 70 % in the combination type
(16).
Prednisone
was one of the first medications used for APLAs positive pregnant women (17).
Due to the associated maternal and fetal complications from its long term use
(diabetes, hypertension, prematurity) prednisone is no more recommended by most
investigators. Similar maternal complications were reported during the study
performed in our center (18). However, prednisone cannot be excluded from the
treatment protocol, as some of the cases may be associated with active systemic
lupus erythromatosis. Prednisone treatment should be prescribed in centers
where physicians experienced in its use for such indications, with close
follow-up of the maternal condition during pregnancy for both the disorder and
the complications of the therapy.
Conclusion and Recommendation
An
important component in the management of couples with RPL is the establishment
of a correct diagnosis. It is important to remember that several factors may be
integrated in the etiology at the same time. Therefore, it is advised not to
stop the evaluation protocol as soon as the first factor has been detected.
For a
significant proportion of RPL couples, no definite cause can be reached. For
these, reassurance is important, as with care and sympathy, pregnancy can reach
term in near 70 % of these cases.
As technical, diagnostic, and therapeutic approaches to
RPL continue to improve, it is a hope that the millions of couples who live
this tragedy will have the opportunity to overcome it. This also emphasizes the
need, in our country, for special clinics to deal with a special area of
obstetrics, the couple with recurrent pregnancy loss.
REFERENCES
- Daya S. Recurrent spontaneous early
pregnancy loss and low dose aspirin. Minerva Gynecol. 2003; 55 (5):441-449.
-
Darmochwal-Kolarz D.,
Leszczynska-Gorzelak B., Rolinski J., Oleszczuk J. The immunophenotype of
patients with recurrent pregnancy loss. Europ J Obstet Gynecol Reprod Biol
2002; 103: 53-57
- Gaber KR, Sanad SA. Recurrent early
pregnancy loss: is cytogenetic study a must before next pregnancy? J Egyp Soc
Obstet Gynecol 1999; 25: 65 1-660
- Creasy MR, Crolla JA, Alberma ED. A
cytogenetic study of human spontaneous abortions using banding techniques. Hum
Genet 1976; 31: 177-196
- Warbuton D, Stein Z, Kline J, Susser M.
Chromosome abnormalities in spontaneous abortion: data from the New York City
Study. In: Porter IH, Hook EB, editors. Human embryonic and fetal death.
Academic, New York 1980: 26 1-287
- Grimbizis GF, Camus M, Tarlatzis
BC, Bontis IN, Devroey P. Clinical implications of uterine malformations and
hysteroscopic treatment results. Hum Reprod Update 2001 ;7: 161-174
- Homer I-IA, Li TC, Cooke ID. The
septate uterus: a review of management and reproductive outcome. Fertil Steril
2000; 73: 1-14
- Althuisius SM, Dekker GA, Hummel P,
van Geijn HP; Cervical incompetence prevention randomized cerclage trial.
Cervical incompetence prevention randomized cerclage trial: emergency cerclage
with bed rest versus bed rest alone. Am J Obstet Gynecol. 2003; 189(4):907-910
-
Daya S. Efficacy of progesterone
support for pregnancy in women with recurrent miscarriage. A meta-analysis of
controlled trials. Br J Obstet Gynecol 1989;96:275-280
- Oates-Whitehead R, Haas D, Carrier J. Progestogen for
preventing miscarriage. Cochrane Database Syst Rev. 2003;4:CD0035 11
- Clifford K, Rai R, Watson H, Franks 5, Regan L. Does
suppressing luteinizing hormone secretion reduce the miscarriage rate? Results
of a randomized controlled trial. BMJ 1996; 312:150815 11.
- Jakubowicz GJ, luorno MJ, Jakubowicz 5, Roberts KA and
Nestler JE. Effects of Metformin on Early Pregnancy Loss in the Polycystic
Ovary Syndrome. J Clinical Endocrinol Metabol 2002; 87: 524-529
- Kutteh WH. Antiphospholipid antibody-associated
recurrent pregnancy loss: treatment with heparin and low-dose aspirin is
superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:
1584-1589
- Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan
ZS, Lavenne-Pardonge E, et al Safety of low-molecular-weight heparin in
pregnancy: a systematic review. Thromb Haemost 1999;8 1:668-672
- Kutteh WH. Antiphospholipid antibody-associated
recurrent pregnancy loss: treatment with heparin and low-dose aspirin is
superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 15 84-1589
- Rai R, Cohen H, Dave M, Regan L. Randomized controlled
trial of aspirin and aspirin plus heparin in pregnant women with recurrent
miscarriage associated with phospholipids antibodies (or antiphospholipid
antibodies). BMJ 1 997;314:253-257
- Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Fetal survival after
prednisone suppression of maternal lupus-anticoagulant. Lancet 1983 ;i:
1361-1363
-
Gaber KR, Amin SN, Farag MK, Hassan
A. Antiphospholipid syndrome: prenatal therapy evaluation. Med J Cairo Univ 2001;
69: 353-357
Dr. Khaled R. Gaber, Ph.D.
Assistant Professor and Head of Prenatal Diagnosis and Fetal Medicine,
Department National Research Center,
Cairo, Egypt
Copyright © Middle East Fertility Society
|